Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 6 | 2023 | 122 | 1.020 |
Why?
|
| Community Health Centers | 3 | 2013 | 89 | 0.790 |
Why?
|
| Public Health | 2 | 2013 | 174 | 0.720 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2007 | 206 | 0.650 |
Why?
|
| Exercise | 4 | 2013 | 883 | 0.600 |
Why?
|
| Telemedicine | 1 | 2023 | 307 | 0.600 |
Why?
|
| Anticoagulants | 5 | 2020 | 477 | 0.590 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2013 | 211 | 0.590 |
Why?
|
| Medicare Part D | 1 | 2017 | 37 | 0.570 |
Why?
|
| Cost Savings | 1 | 2017 | 52 | 0.560 |
Why?
|
| Primary Health Care | 2 | 2013 | 643 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 635 | 0.530 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 68 | 0.510 |
Why?
|
| Polypharmacy | 1 | 2016 | 61 | 0.500 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 23 | 0.490 |
Why?
|
| Aspirin | 2 | 2013 | 166 | 0.490 |
Why?
|
| Pancreatitis | 1 | 2016 | 95 | 0.490 |
Why?
|
| Venous Thromboembolism | 4 | 2020 | 141 | 0.440 |
Why?
|
| Ticlopidine | 3 | 2013 | 45 | 0.440 |
Why?
|
| Warfarin | 2 | 2014 | 105 | 0.430 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 292 | 0.420 |
Why?
|
| Stroke | 3 | 2013 | 1127 | 0.330 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 34 | 0.270 |
Why?
|
| Hemorrhage | 6 | 2018 | 260 | 0.260 |
Why?
|
| Humans | 26 | 2023 | 59360 | 0.240 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2006 | 167 | 0.240 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 805 | 0.240 |
Why?
|
| Angina, Unstable | 1 | 2004 | 56 | 0.230 |
Why?
|
| Coronary Disease | 1 | 2006 | 244 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2018 | 677 | 0.230 |
Why?
|
| Tyrosine | 1 | 2004 | 92 | 0.230 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2023 | 3 | 0.220 |
Why?
|
| Anemia, Hemolytic | 1 | 2023 | 12 | 0.220 |
Why?
|
| Coronary Artery Disease | 3 | 2016 | 273 | 0.210 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 159 | 0.210 |
Why?
|
| Quinolones | 1 | 2023 | 27 | 0.210 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2003 | 20 | 0.210 |
Why?
|
| Computers, Handheld | 1 | 2003 | 38 | 0.210 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 61 | 0.210 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 84 | 0.200 |
Why?
|
| Urban Population | 1 | 2023 | 179 | 0.200 |
Why?
|
| Documentation | 1 | 2003 | 127 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 515 | 0.180 |
Why?
|
| Pharmaceutical Services | 2 | 2017 | 31 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6071 | 0.160 |
Why?
|
| Pandemics | 1 | 2023 | 615 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 170 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 862 | 0.150 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 441 | 0.140 |
Why?
|
| Pharmacies | 1 | 2017 | 34 | 0.140 |
Why?
|
| Male | 11 | 2020 | 27739 | 0.140 |
Why?
|
| Rivaroxaban | 2 | 2014 | 19 | 0.130 |
Why?
|
| Dabigatran | 2 | 2014 | 20 | 0.130 |
Why?
|
| Pyridones | 2 | 2014 | 37 | 0.130 |
Why?
|
| Female | 11 | 2020 | 30705 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2014 | 65 | 0.130 |
Why?
|
| Hospitalization | 3 | 2020 | 1290 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 453 | 0.130 |
Why?
|
| Benzazepines | 1 | 2016 | 21 | 0.130 |
Why?
|
| Massachusetts | 3 | 2017 | 2002 | 0.120 |
Why?
|
| Adult | 7 | 2023 | 15669 | 0.120 |
Why?
|
| Aged | 6 | 2017 | 13416 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 191 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 158 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2016 | 242 | 0.110 |
Why?
|
| Dipyridamole | 1 | 2013 | 17 | 0.110 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 7 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2013 | 8 | 0.110 |
Why?
|
| Thiophenes | 1 | 2013 | 29 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 452 | 0.100 |
Why?
|
| Morpholines | 1 | 2013 | 86 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 56 | 0.100 |
Why?
|
| Proline | 1 | 2013 | 42 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 151 | 0.100 |
Why?
|
| Fees and Charges | 1 | 2012 | 18 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5284 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2013 | 128 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 104 | 0.100 |
Why?
|
| Anti-Ulcer Agents | 1 | 2011 | 8 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 88 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1021 | 0.100 |
Why?
|
| Middle Aged | 7 | 2016 | 16317 | 0.100 |
Why?
|
| Students, Pharmacy | 1 | 2011 | 12 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 102 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2013 | 715 | 0.090 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 64 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 120 | 0.090 |
Why?
|
| Motor Activity | 1 | 2012 | 333 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 935 | 0.080 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2009 | 4 | 0.080 |
Why?
|
| Risk Factors | 3 | 2013 | 4984 | 0.080 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2009 | 3 | 0.080 |
Why?
|
| Medical Waste Disposal | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2016 | 717 | 0.080 |
Why?
|
| Age Factors | 1 | 2012 | 1504 | 0.080 |
Why?
|
| Health Promotion | 1 | 2012 | 471 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 4267 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 98 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 203 | 0.070 |
Why?
|
| Adolescent | 2 | 2016 | 5824 | 0.070 |
Why?
|
| Child | 1 | 2016 | 4174 | 0.070 |
Why?
|
| United States | 2 | 2017 | 7390 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 210 | 0.070 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 21 | 0.060 |
Why?
|
| Poverty | 1 | 2008 | 281 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 251 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 170 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 283 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 806 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 36 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2004 | 100 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 660 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 724 | 0.050 |
Why?
|
| Pyruvate Kinase | 1 | 2023 | 11 | 0.050 |
Why?
|
| Hemolysis | 1 | 2023 | 38 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2006 | 290 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2011 | 3067 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2003 | 40 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 555 | 0.050 |
Why?
|
| Incidence | 1 | 2006 | 1237 | 0.050 |
Why?
|
| Registries | 1 | 2006 | 801 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 705 | 0.050 |
Why?
|
| Peptides | 1 | 2004 | 549 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 839 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 788 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 97 | 0.040 |
Why?
|
| Premedication | 1 | 2018 | 16 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 489 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 147 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 307 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 356 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 23 | 0.030 |
Why?
|
| Ribavirin | 1 | 2013 | 24 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 40 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2013 | 99 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2013 | 102 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 37 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 165 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 689 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 154 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 306 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2009 | 5 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 23 | 0.020 |
Why?
|
| Environmental Pollution | 1 | 2009 | 12 | 0.020 |
Why?
|
| Training Support | 1 | 2009 | 19 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 39 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2011 | 342 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 853 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 154 | 0.020 |
Why?
|
| Community Participation | 1 | 2008 | 45 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 26 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 117 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 521 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 371 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 208 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 2374 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 745 | 0.020 |
Why?
|
| Thrombosis | 1 | 2007 | 182 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 170 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 550 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 5128 | 0.010 |
Why?
|